Carbamoyl pyridone HIV-1 integrase inhibitors 3. A diastereomeric approach to chiral nonracemic tricyclic ring systems and the discovery of dolutegravir (S/GSK1349572) and (S/GSK1265744)

Journal of Medicinal Chemistry

Volumn 56, Issue 14, 2013, Pages 5901-5916

  Johns, Brian A ^a   Kawasuji, Takashi ^b   Weatherhead, Jason G ^a   Taishi, Teruhiko ^b   Temelkoff, David P ^a   Yoshida, Hiroshi ^b   Akiyama, Toshiyuki ^b   Taoda, Yoshiyuki ^b   Murai, Hitoshi ^b   Kiyama, Ryuichi ^b   Fuji, Masahiro ^b   Tanimoto, Norihiko ^b   Jeffrey, Jerry ^a   Foster, Scott A ^a   Yoshinaga, Tomokazu ^b   Seki, Takahiro ^b   Kobayashi, Masanori ^b   Sato, Akihiko ^b   Johnson, Matthew N ^a   Garvey, Edward P ^a   Fujiwara, Tamio ^b   more..

^a GLAXOSMITHKLINE   (United States)

^b SHIONOGI AND CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOALCOHOL; CARBAMOYL PYRIDONE; DIPYRONE; DOLUTEGRAVIR; ELVITEGRAVIR; GSK 1265744; INTEGRASE INHIBITOR; RALTEGRAVIR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CHELATION; CHIRALITY; CONTROLLED STUDY; DIASTEREOISOMER; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DESIGN; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG POTENCY; DRUG SYNTHESIS; ENZYME ACTIVE SITE; EXPERIMENTAL DOG; EXPERIMENTAL MONKEY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; MALE; NONHUMAN; RAT; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; VIRUS STRAIN;

ANIMALS; DOGS; HELA CELLS; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INTEGRASE INHIBITORS; HUMANS; MACACA FASCICULARIS; MALE; PYRIDONES; RATS; RATS, SPRAGUE-DAWLEY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84880861322     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400645w     Document Type: Article

References (38)

1. UNAIDS Report on the Global AIDS Epidemic; United Nations Program on HIV/AIDS (UNAIDS): Geneva, December, 2012; www.UNAIDS.org.
2. Pendri, A.; Meanwell, N. A.; Peese, K. M.; Walker, M. A. New first and second generation inhibitors of human immunodeficiency virus-1 integrase Expert Opin. Ther. Pat. 2011, 21, 1173-1189
3. Johns, B. A.; Svolto, A. C. Advances in two-metal chelation inhibitors of HIV integrase Expert Opin. Ther. Pat. 2008, 18, 1225-1237
4. Kawasuji, T.; Yoshinaga, T.; Sato, A.; Yodo, M.; Fujiwara, T.; Kiyama, R. A platform for designing HIV integrase inhibitors. Part 1. 2-Hydroxy-3- heteroaryl acrylic acid derivatives as novel HIV integrase inhibitors and modeling of hydrophilic and hydrophobic pharmacophores Bioorg. Med. Chem. 2006, 14, 8430-8445
5. Kawasuji, T.; Fuji, M.; Yoshinaga, T.; Sato, A.; Fujiwara, T.; Kiyama, R. A platform for designing HIV integrase inhibitors. Part 2: A two-metal binding model as a potential mechanism of HIV integrase inhibitors Bioorg. Med. Chem. 2006, 14, 8420-8429
6. Lennox, J. L.; DeJesus, E.; Lazzarin, A.; Pollard, R. B.; Madruga, J. V. R.; Berger, D. S.; Zhao, J.; Xu, X.; Williams-Diaz, A.; Rodgers, A. J.; Barnard, R. J. O.; Miller, M. D.; DiNubile, M. J.; Nguyen, B.-Y.; Leavitt, R.; Sklar, P. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial Lancet 2009, 374, 796-806
7. Ceccherini-Silberstein, F.; Malet, I.; D'Arrigo, R.; Antinori, A.; Marcelin, A.-G.; Perno, C-F Characterization and structural analysis of HIV-1 integrase conservation AIDS Rev. 2009, 11, 17-29
8. Johnson, V. A.; Brun-Vezinet, F.; Clotet, B.; Gunthard, H. F.; Kuritkes, D. R.; Pillay, D.; Schapiro, J. M.; Richman, D. D. Update of the Drug Resistance Mutations in HIV-1 Top. HIV Med. 2010, 18, 156-163
9. Quashie, P. K.; Sloan, R. D.; Wainberg, M. A. Novel therapeutic strategies targeting HIV integrase BMC Med. 2012, 10, 34
10. Goethals, O.; Clayton, R.; Van Ginderen, M.; Vereycken, I.; Wagemans, E.; Geluykens, P.; Dockx, K.; Strijbos, R.; Smits, V.; Vos, A.l; Meersseman, G.; Jochmans, D.; Vermeire, K.; Schols, D.; Hallenberger, S.; Hertogs, K. Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors J. Virol. 2008, 82, 10366-10374
11. Ramanathan, S.; Mathias, A. A.; German, P.; Kearney, B. P. Clinical pharmacokinetic and pharmacodynamic profile of the HIV integrase inhibitor elvitegravir Clin. Pharmacokinet. 2011, 50, 229-244
12. Blanco, J.-L.; Varghese, C.; Rhee, S.-Y.; Gatell, J. M.; Shafer, R. W. HIV-1 Integrase Inhibitor Resistance and Its Clinical Implications J. Infect. Dis. 2011, 203, 1204-1214
13. Kawasuji, T.; Johns, B. A.; Yoshida, H.; Taishi, T.; Taoda, Y.; Murai, H.; Kiyama, R.; Fuji, M.; Yoshinaga, T.; Seki, T.; Kobayashi, M.; Sato, A.; Fujiwara, T. Carbamoyl pyridone HIV-1 integrase inhibitors. 1. Molecular design and establishment of an advanced two-metal binding pharmacophore J. Med. Chem. 2012, 55, 8735-8744
14. Kawasuji, T.; Johns, B. A.; Yoshida, H.; Weatherhead, J. G.; Akiyama, T.; Taishi, T.; Taoda, Y.; Mikamiyama-Iwata, M.; Murai, H.; Kiyama, R.; Fuji, M.; Yoshinaga, T.; Seki, T.; Kobayashi, M.; Sato, A.; Garvey, E. P.; Fujiwara, T. Carbamoyl Pyridone HIV-1 Integrase Inhibitors 2. Bi- and Tricyclic Derivatives Result in Superior Antiviral and Pharmacokinetic Profiles J. Med. Chem. 2013, 56, 1124-1135
15. Johns, B. A.; Kawasuji, T.; Taishi, T.; Taoda, Y.; Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity. WO 2006/116764 A1, 2006.
16. Agrawal, A.; DeSoto, J.; Fullagar, J. L.; Maddali, K.; Rostami, S.; Richman, D. D.; Pommier, Y.; Cohen, S. M. Probing chelation motifs in HIV integrase inhibitors Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 2251
17. Kirschberg, T.; Parrish, J. Metal chelators as antiviral agents Curr. Opin. Drug Discovery Dev. 2007, 10, 460
18. Rogolino, D.; Carcelli, M.; Sechi, M.; Neamati, N. Coord. Chem. Rev. 2012, 256, 3063
19. Pseudo-type HIV assay (PHIV). Garvey, E. P.; Johns, B. A.; Gartland, M. J.; Foster, S. A.; Miller, W. H.; Ferris, R. G.; Hazen, R. J.; Underwood, M. R.; Boros, E. E.; Thompson, J. B.; Weatherhead, J. G.; Koble, C. S.; Allen, S. H.; Schaller, L. T.; Sherrill, R. G.; Yoshinaga, T.; Kobayashi, M.; Wakasa-Morimoto, C.; Miki, S.; Nakahara, K.; Noshi, T.; Sato, A.; Fujiwara, T. The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral Antimicrob. Agents Chemother. 2008, 52, 901-908
20. Minick, D. J.; Rutkowske, R. D.; Miller, L. A. D. Strategies for Successfully Applying Vibrational Circular Dichroism Spectroscopy Am. Pharm. Rev. 2007, 10, 118-123
21. th American Chemical Society National Meeting, Philadelphia, PA, August 19-23, 2012, MEDI-357.
22. Canducci, F.; Marinozzi, M. C.; Sampaolo, M.; Boeri, E.; Spagnuolo, V.; Gianotti, N.; Castagna, A.; Paolucci, S.; Baldanti, F.; Lazzarin, A.; Clementi, M. Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir J. Antimicrob. Chemother. 2010, 65, 425-433
23. Goethals, O.; Vos, A.; Van Ginderen, M.; Geluykens, P.; Smits, V.; Schols, D.; Hertogs, K.; Clayton, R. Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles Virology 2010, 402, 338-346
24. Kobayashi, M.; Yoshinaga, T.; Seki, T.; Wakasa-Morimoto, C.; Brown, K. W.; Ferris, R.; Foster, S. A.; Hazen, R. J.; Miki, S.; Suyama-Kagitani, A.; Kawauchi-Miki, S.; Taishi, T.; Kawasuji, T.; Johns, B. A.; Underwood, M. R.; Garvey, E. P.; Sato, A.; Fujiwara, T. In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor Antimicrob. Agents Chemother. 2011, 55, 813
25. Yoshinaga, T.; Kobayashi, M.; Seki, T.; Kawasuji, T.; Taishi, T.; Sato, A.; Fujiwara, T.; Johns, B.; Hazen, R.; Ferris, R.; Underwood, M. Antiviral Characteristics of S/GSK1265744, an HIV integrase inhibitor dosed by oral or long-acting parenteral injection. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, September 9-12, 2012, H-550.
26. Krishnan, L.; Naraharisetty, H. L.; Hare, S.; Cherepanov, P.; Engelman, A. Structure-based modeling of the functional HIV-1 intasome and its inhibition Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 15910
27. Hare, S.; Vos, A. M.; Clayton, R. F.; Thuring, J. W.; Cummings, M. D.; Cherepanov, P. Molecular mechanisms of retroviral integrase inhibition and the evolution of viral resistance Proc. Natl. Acad. Sci. U. S. A. 2010, 107, 20057
28. Hare, S.; Smith, S. J.; Métifiot, M.; Jaxa-Chamiec, A.; Pommier, Y.; Hughes, S. H.; Cherepanov, P. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572) Mol. Pharmacol. 2011, 80, 565
29. Liver blood flow values used (mL/min/kg) were 55 (rat), 31 (dog), and 44(monkey) according to Davies, B.; Morris, T. Physiological parameters in laboratory animals and humans Pharm. Res. 1993, 10, 1093
30. Min, S.; Song, I.; Borland, J.; Chen, S.; Lou, Y.; Fujiwara, T.; Piscitelli, S. Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers Antimicrob. Agents Chemother. 2010, 54, 254-258
31. Min, S.; Sloan, L.; DeJesus, E.; Hawkins, T.; McCurdy, L.; Song, I.; Stroder, R.; Chen, S.; Underwood, M.; Fujiwara, T.; Piscitelli, S.; Lalezari, J. Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults AIDS (Hagerstown, MD, U. S.) 2011, 25, 1737-1745
32. Lunzen, J. v.; Maggiolo, J. R.; Rakhmanova, A.; Yeni, P.; Young, B.; Rockstroh, J. K.; Almond, S.; Song, I.; Brothers, C.; Min, S. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial Lancet Infect. Dis. 2012, 12, 111-118
33. Raffi, F.; Rachlis, A.; Stellbrink, H. -J.; Hardy, W. D.; Torti, C.; Orkin, C.; Bloch, M.; Podzamczer, D.; Pokrovsky, V.; Pulido, F.; Almond, S.; Margolis, D.; Brennan, C.; Min, S. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet 2013, in press
34. Walmsley, S.; Antela, A.; Clumeck, N.; Duiculescu, D.; Eberhard, A.; Gutiérrez, F.; Hocqueloux, L.; Maggiolo, F.; Sandkovsky, U.; Granier, C.; Wynne, B.; Pappa, K. Dolutegravir (DTG; S/GSK1349572) + Abacavir/Lamivudine Once Daily Statistically Superior to Tenofovir/Emtricitabine/Efavirenz: 48-Week Results-SINGLE (ING114467). 52nd Interscience Conference on Antimicrobials and Chemotherapy (ICAAC), San Francisco, CA, September 9-12, 2012, H-556b.
35. Min, S.; DeJesus, E.; McCurdy, L.; Richmond, G.; Torres, J.; Ford, S.; Chen, S.; Lou, Y.; Bomar, M.; Cyr, T.; St. Clair, M.; Fujiwara, T.; Piscitelli, S. Pharmacokinetics (PK) and Safety in Healthy and HIV-Infected Subjects and Short-Term Antiviral Efficacy of S/GSK1265744, a Next Generation Once Daily HIV Integrase Inhibitor. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, September 12-15, 2009, H-1228.
36. Spreen, W.; Ford, S. L.; Chen, S.; Gould, E.; Wilfret, D.; Subich, D.; Taishi, T.; Hong, Z. Pharmacokinetics, Safety and Tolerability of the HIV Integrase Inhibitor S/GSK1265744 Long Acting Parenteral Nanosuspension Following Single Dose Administration to Healthy Adults. XIX International AIDS Conference, Washington DC, July 22-27, 2012, TUPE040.
37. Hazuda, D. J.; Hastings, J. C.; Wolfe, A. L.; Emini, E. A. A novel assay for the DNA strand-transfer reaction of HIV-1 integrase Nucleic Acids Res. 1994, 22, 1121-1122
38. Jarmy, G.; Heinkelein, M.; Weissbrich, B.; Jassoy, C.; Rethwilm, A. Phenotypic analysis of the sensitivity of HIV-1 to inhibitors of the reverse transcriptase, protease, and integrase using a self-inactivating virus vector system J. Med. Virol. 2001, 64, 223-231